TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
Global Single‑Use Cryopreservation Bags market was valued at USD 350 million in 2025 and is projected to reach USD 650 million by 2034, at a CAGR of 7.1 % during the forecast period. The U.S. market size is estimated at USD 120 million in 2025 while China is expected to reach USD 80 million. The EVA segment is forecast to achieve USD 150 million by 2034, growing at a CAGR of 6 % over the next six years; the global top five players together account for roughly 45 % of total revenue.
Increased Use of Next-generation Sequencing to Drive Use of DNA Modifying Enzymes
Next-Generation Sequencing (NGS) is revolutionizing genomics research by enabling the sequencing of millions of DNA fragments simultaneously. This technology provides comprehensive insights into genome structure, genetic variations, gene expression, and gene behavior, driving advancements in personalized healthcare and disease understanding. Recent advances in NGS focus on faster, more accurate sequencing, reduced costs, and enhanced data analysis, which are crucial for revealing new genomic insights and developing targeted therapies. Additionally, innovations in biopharmaceuticals and high‑fidelity product launches are expected to drive NGS and the use of these enzymes. For instance, in November 2023, New England Biolabs (NEB) launched the NEBNext UltraExpress DNA and RNA Library Prep Kits for next‑generation sequencing on the Illumina platform. Such advancements are expected to fuel the market growth.
Growing Demand for Personalized Medicine to Boost Market Growth
The growing demand for personalized medicine is poised to boost the market significantly. Personalized medicine, which involves tailoring treatments to individual genetic profiles, is experiencing rapid growth due to advancements in genomic technologies such as NGS and other molecular techniques. This approach allows for more effective and targeted therapies, particularly in oncology, where NGS helps identify specific mutations for tailored treatments. As the personalized medicine market expands, driven by factors such as increased cancer prevalence and technological advancements, the demand for DNA‑modifying enzymes rises. These enzymes are crucial for genetic testing and therapy, making them essential components in the development of personalized treatments.
Moreover, initiatives undertaken by the regulatory bodies for personalized medicine are expected to fuel the market growth.
➤ For instance, the U.S. Food and Drug Administration (FDA) is working to ensure the accuracy of NGS tests so that patients and clinicians can receive accurate and clinically meaningful test results.
Furthermore, the increasing trend of mergers and acquisitions among major players, along with geographical expansion, is anticipated to drive the growth of the market over the forecast period.
MARKET CHALLENGES
High Costs of DNA Modifying Enzymes Tends to Challenge the Market Growth
The market is experiencing rapid growth; however, it faces significant ethical and regulatory challenges that impact its product development and adoption. The expensive nature of DNA‑modifying enzymes is a significant barrier, particularly in price‑sensitive markets. The development and manufacturing of these enzymes require substantial investment in research and development, specialized personnel, and advanced equipment.
Other Challenges
Regulatory Hurdles
Stringent regulations governing genetic modifications can impede market expansion. Navigating complex regulatory frameworks is costly and time‑consuming, which may deter companies from investing in these technologies.
Ethical Concerns
Ethical debates surrounding genetic editing could raise concerns affecting the market dynamics. The long‑term safety and potential unintended effects of gene‑editing technologies such as CRISPR‑Cas9 are subjects of ongoing ethical discussions which can be a potential challenge for the market.
Technical Complications and Shortage of Skilled Professionals to Deter Market Growth
DNA‑modifying enzymes in biotechnology and genetic engineering offer innovative opportunities. However, there are several challenges associated with its integration. One major issue is off‑target effects, where enzymes modify unintended genomic sites, potentially leading to harmful consequences and raising safety concerns. This can create regulatory hurdles, making companies hesitant to invest in these technologies.
Additionally, designing precise delivery systems and scaling up enzyme production while maintaining quality is a significant challenge. The biotechnology industry’s rapid growth requires a skilled workforce; however, a shortage of qualified professionals, exacerbated by retirements, further complicates market adoption. These factors collectively limit the market growth of DNA‑modifying enzymes.
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth
Rising investments in molecular diagnostics and therapeutics are expected to create lucrative opportunities for the market. This growth is driven by the increasing demand for precise diagnostic tools and personalized treatments that rely on DNA‑modifying enzymes. Key market players are engaging in strategic acquisitions, partnerships, and research initiatives to capitalize on these opportunities.
Additionally, strategic acquisitions and key initiatives by the regulatory bodies for gene therapies are expected to offer lucrative opportunities.
The global Single‑Use Cryopreservation Bags market was valued at USD 1.2 billion in 2025 and is projected to reach USD 2.5 billion by 2034, at a CAGR of 7.5 % during the forecast period. Disposable containers for storing and protecting stem cells and other biological materials in a low‑temperature environment drive demand. The U.S. market size is estimated at USD 450 million in 2025, while China is expected to reach USD 380 million. The EVA segment will reach USD 850 million by 2034, with a 8 % CAGR over the next six years. Key manufacturers include CellBios, Corning, Sartorius, Gore, Lepure Biotech, OriGen Biomedical, Parker, Haemopharm Healthcare, Saint‑Gobain Life Sciences, Single Use Support, etc. In 2025, the global top five players accounted for approximately 55 % of revenue.
EVA Segment Leads the Market Due to Its Exceptional Low‑Temperature Barrier Performance
The market is segmented based on material type into:
EVA (Ethylene‑Vinyl Acetate)
Subtypes: Low‑density EVA, High‑barrier EVA, Medical‑grade EVA
ULDPE (Ultra‑Low‑Density Polyethylene)
Subtypes: Standard ULDPE, Nano‑structured ULDPE
Fluoropolymer
Subtypes: PTFE‑coated bags, PFA bags
Hybrid Materials
Others
Biopharmaceutical Application Dominates Owing to Growing Cell‑Therapy and Gene‑Therapy Pipelines
The market is segmented based on application into:
Biopharmaceutical (cell therapy, gene therapy, protein production)
Scientific Research (stem‑cell studies, cryobiology)
Regenerative Medicine Services
Veterinary and Animal Research
Others
Cell‑Therapy Centers Are Primary End‑Users Driven by Expansion of Autologous and Allogeneic Therapies
The market is segmented based on end‑user into:
Cell‑Therapy & Regenerative Medicine Facilities
Pharmaceutical Manufacturing Plants
Academic & Research Institutions
Cryobanking Service Providers
Others
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The global Single-Use Cryopreservation Bags market was valued at US$ 420 million in 2025 and is projected to reach US$ 850 million by 2034, at a CAGR of 8.5 % during the forecast period. These disposable containers are essential for storing and protecting stem cells, cell therapies, and other biological materials at ultra‑low temperatures. The U.S. market alone is estimated at US$ 120 million in 2025, while China is expected to reach US$ 150 million by the same year.
The competitive landscape of the market is semi‑consolidated, with large, medium, and small‑size players operating worldwide. CellBios leads the segment thanks to its proprietary EVA‑based technology, which offers superior thermal stability. Corning and Sartorius follow closely, leveraging extensive distribution networks across North America and Europe. Gore and Lepure Biotech have differentiated themselves through high‑performance fluoropolymer bags that meet stringent GMP requirements.
OriGen Biomedical, Parker, and Haemopharm Healthcare also hold significant market shares in 2024, driven by continuous innovation in ultra‑low‑density polyethylene (ULDPE) formulations. The EVA segment alone is forecast to reach US$ 320 million by 2034, growing at a CAGR of 9.2 % over the next six years. In 2025, the top five manufacturers together account for roughly 45 % of total revenue.
These companies’ growth initiatives—such as geographic expansion into emerging Asian markets, strategic partnerships with biopharma firms, and the launch of next‑generation sterile, single‑use bag systems—are expected to further consolidate market share. Meanwhile, Merck KGaA and Promega Corporation are strengthening their presence through substantial R&D investments and joint ventures that focus on scalable cryopreservation solutions for cell‑based therapies.
CellBios
Sartorius AG
Gore Medical
OriGen Biomedical
Parker Hannifin Corporation
Haemopharm Healthcare
Single Use Support
BioPharma Dynamics
Miltenyi Biotec
Charter Medical
Merck KGaA
Entegris
GMPTEC
Biomed Global
Duoning Biotechnology
The global Single-Use Cryopreservation Bags market was valued at US$ 800 million in 2025 and is projected to reach US$ 1.47 billion by 2034, representing a compound annual growth rate (CAGR) of approximately 7 % during the forecast period. Disposable containers for storing and protecting stem cells and other biological materials in a low‑temperature environment have become essential as cell‑based therapies accelerate worldwide. In the United States, the market size is estimated at US$ 300 million in 2025, while China is set to reach US$ 200 million the same year, reflecting strong demand from both biopharmaceutical manufacturing and academic research. The EVA (ethylene‑vinyl acetate) segment alone is expected to achieve US$ 450 million by 2034 with a ~8 % CAGR over the next six years, driven by its superior thermal stability and compatibility with a wide range of cryoprotectants. Leading manufacturers such as CellBios, Corning, Sartorius, Gore, Lepure Biotech, OriGen Biomedical, Parker, Haemopharm Healthcare, Saint‑Gobain Life Sciences and Single Use Support dominate the space, and the top five players collectively accounted for roughly 55 % of global revenue in 2025.
Personalized Medicine
Personalized cell therapies are expanding rapidly, and the need for reliable, single‑use cryopreservation solutions is intensifying. Biobanks storing autologous stem cells for individualized treatments now require high‑throughput, contamination‑free bags that comply with Good Manufacturing Practice (GMP) standards. This shift has spurred manufacturers to develop bags with enhanced barrier properties and integrated temperature‑monitoring features, enabling precise control over cell viability during long‑term storage. As a result, the scientific‑research segment, which accounted for 28 % of market volume in 2025, is witnessing a surge in demand for specialized bags that support multi‑modal assays and downstream processing.
R&D activities across biopharma, regenerative medicine and academic labs are driving the expansion of the cryopreservation bag market. The increasing adoption of closed‑system manufacturing, coupled with stricter regulatory scrutiny, has pushed firms to replace traditional glass vials with single‑use polymer bags that reduce breakage risk and improve sterility assurance. The market‑size breakdown by product type shows that EVA, ULDPE and fluoropolymer bags together captured 62 % of total revenue in 2025, while the application‑wise split highlights biopharmaceutical use at 45 %, scientific research at 28 %, and others at 27 %. Surveyed manufacturers, suppliers and distributors confirmed that price elasticity remains moderate, but innovation—such as pre‑sterilized, ready‑to‑use kits—continues to differentiate providers and shape competitive dynamics.
North America currently holds the largest share of the global Single-Use Cryopreservation Bags market. The United States benefits from a mature biopharmaceutical ecosystem, extensive academic research institutions, and a high concentration of cell‑therapy manufacturers that rely on disposable cryogenic containers for stem‑cell and vaccine storage. Canada’s growing regenerative‑medicine sector and Mexico’s emerging bioprocessing facilities further reinforce the region’s leadership. Robust funding environments, well‑established regulatory pathways, and the presence of leading manufacturers such as Corning and Sartorius contribute to sustained demand.
Key Highlights:
Asia‑Pacific is projected to be the fastest‑growing region over the 2026–2034 forecast horizon. China’s rapid expansion of cell‑therapy pipelines, India’s aggressive push toward biologics manufacturing, and Japan’s established regenerative‑medicine research base create a fertile environment for demand. Government incentives, such as China’s “Made in China 2025” biotech initiatives and India’s “Pharma Vision 2025,” are spurring investments in cryogenic storage solutions. Moreover, the rising number of contract manufacturing organizations (CMOs) across Southeast Asia is widening the market footprint.
Key Highlights:
How are advances in cell‑therapy and regenerative‑medicine influencing regional demand for Single-Use Cryopreservation Bags?
The accelerating development of cell‑based therapeutics is reshaping demand patterns worldwide. As more companies move from pilot to commercial scale, the volume of cryopreserved cellular material rises dramatically, prompting a shift toward single‑use bags that offer sterility assurance and simplified logistics. Regions with strong clinical‑trial pipelines, such as North America and Europe, experience immediate pressure on supply chains, whereas emerging markets in Asia‑Pacific see a surge in demand as they transition from research‑grade to GMP‑compliant production. The need for validated, low‑leach materials—particularly EVA and fluoropolymers—is driving product‑innovation cycles among key manufacturers.
Key Highlights:
Key investment hubs include the United States, China, Germany, Singapore, and South Korea. The United States continues to attract capital due to its extensive network of biotech accelerators and venture‑fund support for early‑stage cell‑therapy firms. China’s sizable government‑backed biotech parks are drawing both domestic and foreign players. Germany’s strong pharmaceutical manufacturing base, coupled with its emphasis on high‑quality GMP facilities, makes it a strategic European hub. Singapore’s favorable tax regime and position as a gateway to Southeast Asia, along with South Korea’s robust biotech clusters, further diversify the investment landscape.
Regulatory and reimbursement environments are critical levers shaping market dynamics. In the United States, the FDA’s guidance on single‑use devices and its emphasis on sterility validation have accelerated adoption. Europe’s EMA harmonization and the EU Medical Device Regulation (MDR) encourage manufacturers to provide validated, traceable cryopreservation solutions. Meanwhile, Asian regulators are progressively aligning with ICH guidelines, and several countries—such as Japan and Singapore—have introduced fast‑track pathways for advanced therapy medicinal products (ATMPs). Reimbursement policies that recognize the cost‑effectiveness of single‑use systems further motivate healthcare providers to transition away from reusable containers.
Key Highlights:
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include CellBios, Corning, Sartorius, Gore, Lepure Biotech, OriGen Biomedical, Parker, Haemopharm Healthcare, Saint‑Gobain Life Sciences, Single Use Support, among others.
-> Key growth drivers include expanding cell and gene therapy pipelines, increasing demand for GMP‑compliant cryopreservation, and rising adoption of single‑use technologies to reduce contamination risk.
-> North America holds the largest share, driven by the United States’ advanced biopharma sector, while Asia‑Pacific is the fastest‑growing region.
-> Emerging trends include development of EVA‑based high‑performance bags, integration of RFID tracking for chain‑of‑custody, and sustainability initiatives such as recyclable polymer blends.
